Citicoline Sodium / CAS 33818-15-4

Citicoline is a kind of nucleic acid derivative. In 1956, Geiger found that citicoline can make brain injury recover; Kennedy's research in 1957 confirmed that it was very important in the synthesis of brain phospholipids. In 1961, Takeda pharmaceutical company of Japan developed and produced this product, which was registered in China in 1988. It plays an important role in the synthesis of lecithin and improves brain function by promoting the synthesis of lecithin. Experiments have shown that citicoline can enhance the levels of norepinephrine and dopamine in the central nervous system, so as to treat cerebrovascular disease, brain trauma and cognitive impairment caused by various reasons, and has no obvious side effects. Citicoline sodium can enhance the brain stem reticular formation, especially the ascending reticular formation closely related to consciousness, activate the function of the system, enhance the role of the pyramidal system, inhibit the role of the extrapyramidal system, and promote recovery. At the same time, it can reduce cerebral vascular resistance, increase cerebral blood perfusion and promote cerebral material metabolism. It is mainly used in the treatment of neurological sequelae caused by brain injury and cerebrovascular accident, and can be used in the treatment of Parkinson's disease, and has certain curative effect on Alzheimer's disease; For the treatment of cerebrovascular and cardiovascular diseases; Others, such as delaying aging, improving learning effect and memory, also have certain curative effect.